Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

PANACEA BIOTEC LTD. - 531349 - I. Audited Financial Results (Standalone And Consolidated) For The Quarter / Financial Year Ended March 31, 2020 Ii. Passing Over Of Dividend For The Financial Year 2019-20

 We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 29.06.2020, inter-alia, considered and approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter/ financial year ended March 31, 2020. The same were also reviewed by the Audit Committee in its meeting held on June 29, 2020. Further, we would like to confirm that the Auditors' Report on the Audited Financial Results (Standalone and Consolidated) for the financial Year ended March 31, 2020 is with unmodified opinion. Further, in view of losses, the Board of Directors has not recommended any dividend on the Preference as well as Equity Shares of the Company for the financial year ended March 31, 2020. The meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 6:40 P.M.
29-06-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated June 17, 2020 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper advertisements regarding Notice of Postal Ballot and Remote E-voting information published on June 19, 2020 in the following newspapers:- ? Business Standard, All Editions ? Desh Sewak, Punjabi Edition
19-06-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated June 17, 2020 intimating the date of proposed Board Meeting scheduled to be held on June 29, 2020, for approving the Standalone and Consolidated Audited Financial Results for the Quarter / Financial Year ended March 31, 2020 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of the notice of Board Meeting published in the following newspapers on June 19, 2020:- Business Standard (English); Desh Sewak (Punjabi)
19-06-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Board Meeting Intimation for Approving The Standalone And Consolidated Audited Financial Results For The Quarter / Financial Year Ended March 31, 2020

 PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/06/2020 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter / Financial Year ended March 31,2020. Further, with reference to our earlier announcement dated March 31, 2020 intimating the Closure of Trading Window pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company till July 01,2020 and the same will re-open from July 02, 2020.
18-06-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 Please find enclosed a copy of the Notice of Postal Ballot ('Notice') being sent to the shareholders through email for the purpose of obtaining approval of the shareholders by way of special resolution on the following matters: 1. Authority for making 50% capital contribution of an amount equivalent upto Euro 25,000 or INR 2.00 million, whichever is higher, in the proposed Joint Venture Company for Covid-19 Vaccine; 2. Approval of 'Panacea Biotec Limited - Employee Stock Option Plan 2020'; and 3. Approval of grant of employee stock options to the employees of the subsidiary company of the Company under Panacea Biotec Limited - Employee Stock Option Plan 2020.
17-06-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 We are pleased to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. June 16, 2020, inter-alia, considered and approved the following: 1.Setting up of a Joint Venture Company in the name of Panacea Refana Ltd. for development, manufacturing and distribution of the Covid-19 vaccine. 2.Seeking shareholders' approval through Postal Ballot for : a.investment in the said Joint Venture Company; and b.approval of 'Panacea Biotec Limited - Employee Stock Option Plan 2020' for the employees of the Company and its Subsidiary Company, Panacea Biotec Pharma Limited.
16-06-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Serum Institute of India Pvt Ltd & PACs
16-06-2020

Expect COVID-19 vaccine to enter phase-1 human trial by October: Panacea Biotec's Rajesh Jain

 Panacea Biotec said the aim is to manufacture over 500 million doses of COVID-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year.
15-06-2020
Bigul

Panacea forms JV with Refana to develop, manufacture Covid-19 vaccine

 The firm is set to make 500 million doses of the vaccine, which will then be supplied to the JV (based in the Republic of Ireland).
10-06-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements

 In continuation to our letter dated June 10, 2020 and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'), we are pleased to inform you that on June 09, 2020, the Company has entered into a Memorandum of Understanding ('MOU') with REFANA Inc. USA, a Delaware corporation incorporated under the laws of the state of Delaware, United States for Covid-19 vaccine for global development, manufacturing and distribution of the Covid-19 vaccine. The detailed disclosure as required under Regulation 30 of SEBI LODR Regulations in respect of the above mentioned matter is provided in the enclosed intimation.
10-06-2020
Next Page
Close

Let's Open Free Demat Account